This article is more than 5 years old. Information may no longer be current.

BioTime names new CEO

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Brian Culley has been appointed as CEO of BioTime, succeeding co-CEOs Adi Mohanty and Michael West, PhD, the company announced in a press release.

BioTime, whose retinal restoration project has successfully grown complete human 3-D retinal tissue derived from human pluripotent cells, is working to address advanced retinal diseases and injuries.

Culley previously served as CEO at Mast Therapeutics, and his experience includes overseeing clinical development of pharmaceutical products from research through phase 3, corporate partnering and institutional capital raising, the release said.

“I am excited for the opportunity to build upon the strong foundation created by Mike, Adi and the rest of the BioTime team. As the company expands the scope of its product candidates, I look forward to contributing my experience running large clinical trials, collaborating with patient and advocacy groups, and creating value through business development initiatives and shareholder awareness campaigns,” Culley said in the release. “I aspire for BioTime to lead the way in the translation of cellular therapies into approved treatments for a wide range of serious diseases and conditions.”